Journal articles
Rodgers WJ, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H, Ford H, Fisniku L, et al (In Press). The Impact of Smoking Cessation on Multiple Sclerosis Disease Progression.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Harrower T, Orrell RW, Annadale J, Hanemann OC, et al (2024). Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.
Amyotroph Lateral Scler Frontotemporal Degener, 1-11.
Abstract.
Author URL.
Young CA, Rog DJ, Sharrack B, Tanasescu R, Kalra S, Harrower T, Tennant A, Mills RJ, Trajectories of Outcome in Neurological Conditions-MS Study Group (2023). Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
Neurol Sci Abstract.
Author URL.
Young CA, Ealing J, McDermott CJ, Williams TL, Al-Chalabi A, Majeed T, Talbot K, Harrower T, Faull C, Malaspina A, et al (2023). Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION,
24(1-2), 63-70.
Author URL.
Young CA, Ealing J, McDermott CJ, Williams TL, Al-Chalabi A, Majeed T, Talbot K, Harrower T, Faull C, Malaspina A, et al (2023). Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months.
Amyotroph Lateral Scler Frontotemporal Degener,
24(1-2), 82-90.
Abstract.
Author URL.
Nicholas R, Harrower T, Su R, Licata S, Vonsy J (2022). 014 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program. Journal of Neurology Neurosurgery & Psychiatry, 93(6), a18.1-a1a18.
Nicholas R, Harrower T, Liao S, Vonsy J (2022). 119 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program. Journal of Neurology Neurosurgery & Psychiatry, 93(6), a138.2-a1a138.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, et al (2022). Long-term Effectiveness of Adjuvant Treatment with Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared with Dopamine Agonists Among Patients with Parkinson Disease Uncontrolled by Levodopa Therapy: the PD MED Randomized Clinical Trial.
JAMA Neurol,
79(2), 131-140.
Abstract.
Author URL.
Young CA, Mills RJ, Langdon D, Rog DJ, Sharrack B, Kalra S, Majeed T, Footit D, Harrower T, Nicholas RS, et al (2022). Measuring coping in multiple sclerosis: the Coping Index-MS.
Mult Scler,
28(14), 2274-2284.
Abstract.
Author URL.
Young CA, McDermott CJ, Williams TL, Ealing J, Majeed T, Al-Chalabi A, Dick DJ, Talbot K, Harrower T, Pinto A, et al (2021). Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: a patient derived, Rasch compliant scale.
J Neurol Sci,
421 Abstract.
Author URL.
Young CA, Mills R, Rog D, Sharrack B, Majeed T, Constantinescu CS, Kalra S, Harrower T, Santander H, Courtald G, et al (2021). Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
J Neurol Sci,
426 Abstract.
Author URL.
Middleton RM, Pearson OR, Ingram G, Craig EM, Rodgers WJ, Downing-Wood H, Hill J, Tuite-Dalton K, Roberts C, Watson L, et al (2020). A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test.
Journal of Medical Internet Research,
22(9), e18234-e18234.
Abstract.
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, et al (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment.
J Crohns Colitis,
14(12), 1653-1661.
Abstract.
Author URL.
Edge R, Mills R, Tennant A, Diggle PJ, Young CA, Al-Chalabi A, Williams TL, Dick DJ, Talbot K, Burke G, et al (2020). Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? a national study reconciling previous conflicting literature.
JOURNAL OF NEUROLOGY,
267(3), 607-615.
Author URL.
Edge R, Mills R, Tennant A, Diggle PJ, Young CA, Al-Chalabi A, Williams TL, Dick DJ, Talbot K, Burke G, et al (2020). Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? a national study reconciling previous conflicting literature (vol 267, pg 607, 2020).
JOURNAL OF NEUROLOGY,
267(3), 616-617.
Author URL.
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho P-R, et al (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Journal of Neurology, Neurosurgery & Psychiatry,
91(6), 660-668.
Abstract.
Young CA, Mills R, Al-Chalabi A, Burke G, Chandran S, Dick DJ, Ealing J, Hanemann CO, Harrower T, Mcdermott CJ, et al (2020). Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF.
Amyotroph Lateral Scler Frontotemporal Degener, 1-9.
Abstract.
Author URL.
Hawton A, Green C, Goodwin E, Harrower T (2019). Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
Eur J Health Econ,
20(9), 1335-1347.
Abstract.
Author URL.
Lennox B, Yeeles K, Jones PB, Zandi M, Joyce E, Yu LM, Tomei G, Pollard R, Vincent SA, Shimazaki M, et al (2019). Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: Study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).
Trials,
20(1).
Abstract.
Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D, Talbot K, et al (2019). The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease.
Amyotroph Lateral Scler Frontotemporal Degener,
20(5-6), 317-327.
Abstract.
Author URL.
Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T, McDermott CJ, et al (2018). Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.
Acta Neurol Scand,
138(1), 47-54.
Abstract.
Author URL.
Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, et al (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet Neurology, 17(5), 405-415.
Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, et al (2018). Outcome of cell suspension allografts in a patient with Huntington's disease.
Ann Neurol,
84(6), 950-956.
Abstract.
Author URL.
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, et al (2018). Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Mult Scler Relat Disord,
24, 3-10.
Abstract.
Author URL.
McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C, Ellis CM, Gorrie G, et al (2017). A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener,
18(1-2), 1-9.
Abstract.
Author URL.
Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J (2017). Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
Clinicoecon Outcomes Res,
9, 211-229.
Abstract.
Author URL.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al (2017). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 376(3), 221-234.
Dinet J, Desai K, Brand S, Abogunrin S, Gabriel S, Harrower T (2015). 61. AbobotulinumtoxinA in the management of cervical dystonia (CD) in the United Kingdom (UK): a budget impact analysis (BIA). Toxicon, 93
Abogunrin S, Brand S, Desai K, Dinet J, Gabriel S, Harrower T (2015). AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.
Clinicoecon Outcomes Res,
7, 441-449.
Abstract.
Author URL.
Greaves RF, Woollard GA, Hoad KE, Walmsley TA, Johnson LA, Briscoe S, Koetsier S, Harrower T, Gill JP (2014). Laboratory medicine best practice guideline: Vitamins A, E and the carotenoids in blood.
Clinical Biochemist Reviews,
35(2), 81-113.
Abstract.
PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, et al (2014). Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Lancet,
384(9949), 1196-1205.
Abstract.
Author URL.
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, et al (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
Nature Genetics,
45(11), 1353-1362.
Abstract.
Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J, Ellis CM, Gorrie G, et al (2013). Management of sialorrhoea in motor neuron disease: a survey of current UK practice.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,
14(7-8), 521-527.
Abstract.
Alkufri F, Harrower T, Rahman Y, Hughes E, Mundy H, Knibb JA, Moriarty J, Connor S, Samuel M (2013). Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome.
MOVEMENT DISORDERS,
28(3), 399-400.
Author URL.
Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, et al (2013). The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY,
84(6), 657-665.
Author URL.
Orth M, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB, Bachoud-Levi A-C, Bentivoglio AR, Biunno I, et al (2011). Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY,
82(12), 1409-+.
Author URL.
Ganesan D, Higgins JNP, Harrower T, Burnet NG, Sarkies NJC, Manford M, Pickard JD (2008). Stent placement for management of a small parasagittal meningioma. Technical note.
J Neurosurg,
108(2), 377-381.
Abstract.
Author URL.
Harrower TP, Tyers P, Hooks Y, Barker RA (2006). Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease. Experimental Neurology, 197(1), 56-69.
Harrower T, Barker RA (2005). Cell therapies for neurological disease--from bench to clinic to bench.
Expert Opin Biol Ther,
5(3), 289-291.
Abstract.
Author URL.
Harrower TP, Barker RA (2004). Is There a Future for Neural Transplantation?. BioDrugs, 18(3), 141-153.
Harrower T, Ratcliffe E, Richards A, Dunnett S, Bark R (2002). Long-Term Survival of Porcine Expanded Neural Precursors in the Rat Model of Parkinson's Disease. Clinical Science, 103(s47), 67p-67p.
Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, et al (2002). Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.
J Neurol Neurosurg Psychiatry,
73(6), 678-685.
Abstract.
Author URL.
Harrower T, Cruz G, Copeman L, Richards A, Dunnett S, Barker R (2001). MHC and α Gal Expression in Porcine Fetal Neural Tissue. Clinical Science, 100(s44), 13p-13p.